Morgan Stanley Keeps BridgeBio Pharma at Overweight, Lifts Target to $91
Morgan Stanley maintained its Overweight rating on BridgeBio Pharma and raised its price target to $91 from $88, according to Dow Jones Newswires.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Morgan Stanley analysts kept their Overweight rating on BridgeBio Pharma (BBIO), a biopharmaceutical company. The bank lifted its price target on the stock to $91 from $88.
Dow Jones Newswires reported the move on November 13, 2026 at 18:04 GMT, citing Benzinga's ratings records.
why it matters
Routine analyst actions like this usually move a single stock rather than the broader market. For BBIO holders, it is one more data point on how a major bank views the shares.
tags
instruments
sources
- BridgeBio Pharma Is Maintained at Overweight by Morgan Stanley — Dow Jones Newswires, 13 November 2026 at 18:04 UTC
- BeOne Medicines Is Maintained at Overweight by Morgan Stanley — Dow Jones Newswires, 13 November 2026 at 18:08 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗